• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

TRACON Pharmaceuticals

edit

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, develops, licenses, and commercializes targeted therapies for cancer and age-related macular degeneration. Its products include TRC093, a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth, and cancer metastasis by binding cleaved collagen in the extracellular matrix of solid tumors; TRC105, a human chimeric monoclonal antibody that binds endoglin for angiogenesis; TRC102, a molecule that reverses resistance to chemotherapeutics; and TRC101, a nanoliposome embedded with ceramide used to improve the activity and delivery of chemotherapeutics. TRACON Pharmaceuticals, Inc. was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in April 2005. The company was founded in 2005 and is based in San Diego, California.

Recent Milestones

edit

• 
  TRACON Pharmaceuticals received $14M in Series A funding. (4/20/11)
  Posted 4/20/11 at 10:11pm via traconpharma.com
• 
  TRACON Pharmaceuticals added Charles P. Theuer as President and CEO.
  Posted 4/20/11 at 10:11pm

Videos

Screenshots

edit

Sources

1. TRACON Pharmaceuticals announces $22 million tranched investment led by JAFCO and Nextech to fund TRC105 Phase 2 development (traconpharma.com) [edit]